Mavacamten Significantly Reduces Myocardial Stress and Injury in Nonobstructive HCM: Insights From the ODYSSEY-HCM Trial
Posted inCardiology news

Mavacamten Significantly Reduces Myocardial Stress and Injury in Nonobstructive HCM: Insights From the ODYSSEY-HCM Trial

While the ODYSSEY-HCM trial missed its primary functional endpoints, a new exploratory analysis reveals that mavacamten significantly reduces NT-proBNP and hs-cTnI levels in patients with nonobstructive hypertrophic cardiomyopathy, suggesting a potent biological effect on myocardial wall stress and chronic injury.
Beyond Peak VO2: VO2T12.5% Emerges as a Cardiospecific Marker of Performance and Therapeutic Response in Obstructive HCM
Posted inCardiology news

Beyond Peak VO2: VO2T12.5% Emerges as a Cardiospecific Marker of Performance and Therapeutic Response in Obstructive HCM

This substudy of the SEQUOIA-HCM trial identifies VO2T12.5% as a novel exercise recovery metric. It uniquely reflects cardiac hemodynamics, predicts clinical outcomes, and demonstrates significant improvement with aficamten therapy, offering a simple yet powerful tool for clinical cardiopulmonary exercise testing.
A Unified High-Sensitivity Cardiac Troponin I Threshold of 80 ng/L for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy
Posted inCardiology news

A Unified High-Sensitivity Cardiac Troponin I Threshold of 80 ng/L for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy

This multicenter study identifies high-sensitivity cardiac troponin I (hs-cTnI) as a potent, independent predictor of mortality in wild-type transthyretin amyloid cardiomyopathy. A universal threshold of 80 ng/L, integrated with natriuretic peptides, provides a robust staging system across multiple assay platforms.
Dose-Dependent Efficacy of Vixarelimab in Prurigo Nodularis: Targeting the OSMRβ Pathway for Itch and Lesion Resolution
Posted inDermatology news

Dose-Dependent Efficacy of Vixarelimab in Prurigo Nodularis: Targeting the OSMRβ Pathway for Itch and Lesion Resolution

This Phase 2b randomized clinical trial demonstrates that vixarelimab, a monoclonal antibody targeting OSMRβ, significantly reduces pruritus and promotes skin lesion clearance in patients with moderate-to-severe prurigo nodularis, offering a potent, dose-dependent therapeutic option with a favorable safety profile.
Tailored Weight Loss Interventions for Veterans with Serious Mental Illness: Efficacy and Implementation Insights from Recent RCT Evidence
Posted inClinical Updates Internal Medicine news Psychiatry

Tailored Weight Loss Interventions for Veterans with Serious Mental Illness: Efficacy and Implementation Insights from Recent RCT Evidence

This review synthesizes evidence from a 2025 randomized clinical trial evaluating a tailored weight loss program, CoachToFit, for veterans with serious mental illness, highlighting its potential to improve weight outcomes via remote support technologies and peer-led interventions.
Causal Insights Into Hidradenitis Suppurativa: Mendelian Randomization Evidence Linking BMI, Inflammatory Bowel Disease, and Smoking
Posted inClinical Updates Dermatology Gastroenterology Internal Medicine news

Causal Insights Into Hidradenitis Suppurativa: Mendelian Randomization Evidence Linking BMI, Inflammatory Bowel Disease, and Smoking

Recent Mendelian randomization analyses demonstrate causal effects of increased BMI and inflammatory bowel disease on hidradenitis suppurativa risk, elucidating modifiable contributions beyond genetic correlations with psoriasis and systemic sclerosis.
Beyond Troponin: Cardiac Myosin-Binding Protein C Accelerates NSTEMI Diagnosis and Emergency Department Triage
Posted inCardiology Emergency Medicine news

Beyond Troponin: Cardiac Myosin-Binding Protein C Accelerates NSTEMI Diagnosis and Emergency Department Triage

A secondary analysis of the APACE study demonstrates that Cardiac Myosin-Binding Protein C (cMyC) significantly improves NSTEMI diagnosis, particularly in early presenters. Integrating cMyC with high-sensitivity troponin into a dual-biomarker strategy doubles triage efficacy without compromising safety, offering a robust tool for busy clinical settings.
Rethinking Radical Surgery: Lobectomy Matches Total Thyroidectomy Outcomes in Intermediate-Risk PTC with Unilateral N1b Disease
Posted inGeneral Surgery news Oncology

Rethinking Radical Surgery: Lobectomy Matches Total Thyroidectomy Outcomes in Intermediate-Risk PTC with Unilateral N1b Disease

A comprehensive meta-analysis suggests that for intermediate-risk papillary thyroid carcinoma with unilateral lateral lymph node metastasis, lobectomy provides oncological outcomes comparable to total thyroidectomy, challenging the necessity of radical resection and adjuvant radioactive iodine in this cohort.
Rethinking Radioactive Iodine Therapy for T1-T2 Papillary Thyroid Carcinoma with Lymph Node Metastasis: A Multicenter Analysis
Posted inDiabetes & Endocrinology news Oncology

Rethinking Radioactive Iodine Therapy for T1-T2 Papillary Thyroid Carcinoma with Lymph Node Metastasis: A Multicenter Analysis

A multicenter study in China demonstrates that radioactive iodine therapy may not significantly improve structural or biochemical response rates in T1-T2 stage papillary thyroid carcinoma with lymph node metastasis, highlighting the lymph node ratio as a more critical predictor of recurrence.
Total Thyroidectomy Superior to Lobectomy for N1b Papillary Thyroid Carcinoma: Longitudinal Data Suggests Age-Dependent Survival Benefits
Posted inGeneral Surgery news Oncology

Total Thyroidectomy Superior to Lobectomy for N1b Papillary Thyroid Carcinoma: Longitudinal Data Suggests Age-Dependent Survival Benefits

A large-scale SEER database study reveals that total thyroidectomy significantly improves disease-specific survival for patients with cN1b papillary thyroid cancer. However, this survival advantage is attenuated in younger populations, potentially opening the door for personalized surgical de-escalation.